Business Context and Reporting Period
Company: Harvard Bioscience, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2005
Business Overview: The Company manufactures and sells scientific instruments and consumables for research, primarily in the pharmaceutical and biotechnology sectors. Operations are divided into two segments: the Apparatus and Instrumentation Business (continuing operations) and the Capital Equipment Business (discontinued operations).
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2005 |
Nine Months Ended Sep 30, 2005 |
Nine Months Ended Sep 30, 2004 |
|---|---|---|---|
| Revenues (Continuing) | $17,179 | $49,591 | $47,318 |
| Gross Profit | $8,505 | $24,157 | $22,878 |
| Gross Margin % | 49.5% | 48.7% | 48.3% |
| Operating Income | $2,384 | $5,419 | $6,389 |
| Net Income (Loss) | $661 | $(26,516) | $1,204 |
| Cash and Equivalents | $11,271 (as of Sep 30, 2005) | ||
| Long-Term Debt | $14,500 (drawn on $20M facility) |
Note: Net loss for the nine months ended Sep 30, 2005, is heavily impacted by discontinued operations.
Material Changes vs. Prior Period
- Discontinued Operations: The Company announced plans in July 2005 to divest its Capital Equipment Business segment. Consequently, this segment is reported as discontinued operations. This resulted in a net loss of $27.3 million for the nine months ended September 30, 2005, compared to a net loss of $2.3 million in the same period of 2004.
- Impairment Charges: Significant non-cash charges were recorded in Q2 2005 related to the Capital Equipment segment, including $9.9 million for goodwill impairment and $8.0 million for abandonment and impairment of long-lived assets.
- Restructuring: $4.0 million in restructuring charges were recorded for the nine months ended Sep 30, 2005, primarily for inventory write-offs ($3.5M) and facility closures.
- Continuing Operations Performance:
- Revenue Growth: Revenues from continuing operations increased 4.8% year-over-year for the nine-month period, driven by growth at the Biochrom subsidiary and the KD Scientific acquisition.
- Expense Increases: General and administrative expenses rose 19.3% year-over-year, largely due to increased costs associated with Sarbanes-Oxley compliance.
- Tax Provision: Income tax expense for continuing operations increased to $4.0 million (nine months 2005) from $2.3 million (nine months 2004), primarily due to a $4.1 million increase in the valuation allowance for deferred tax assets.
Outlook, Risks, and Management Commentary
- Divestiture Strategy: Management is focusing resources on the Apparatus and Instrumentation segment. Proceeds from the sale of the Capital Equipment segment are intended to repay debt and fund "tuck-under" acquisitions.
- Credit Facility Risk: The sale of the Capital Equipment segment requires lender consent. Failure to obtain consent could trigger a default, allowing lenders to accelerate all outstanding indebtedness ($14.5 million).
- Liquidity and Capital: The Company has $11.3 million in cash and $5.5 million of undrawn capacity on its $20 million credit facility. Management believes resources are sufficient for at least 12 months. However, access to public debt or equity markets is currently restricted until audited financial statements for a previous acquisition are provided.
- Capital Raising: Future capital needs may be met through private equity, additional borrowing, or the sale of the Capital Equipment segment.
- Internal Controls: The Company identified material weaknesses in internal controls over financial reporting related to income tax accounting and the review of material journal entries. Disclosure controls and procedures were deemed ineffective as of September 30, 2005.
- Correction: A material adjustment was required in Q2 2005 to properly state impairment expenses due to these control failures.
- Market Risks: Significant exposure to foreign currency fluctuations (51% of revenue from non-U.S. operations) and dependence on key distributor GE Healthcare (approx. 26% of 2004 revenue).
Investor Verification Checklist
- Divestiture Status: Verify the progress of the Capital Equipment Business sale and whether lender consent has been obtained to avoid credit facility default.
- Internal Control Remediation: Review subsequent filings for updates on the remediation of material weaknesses in internal controls over financial reporting.
- Capital Access: Confirm if the Company has resolved the SEC requirement regarding audited financial statements for previous acquisitions to regain access to public capital markets.
- Deferred Tax Assets: Monitor the valuation allowance for deferred tax assets, which increased significantly in 2005, and assess the likelihood of future realization.
- Continuing Operations Margins: Analyze whether the gross margin expansion in continuing operations is sustainable given the mix of manufactured vs. distributed products.